BioCentury
ARTICLE | Clinical News

Aldeyra gains on Phase IIa data for dry eye candidate

September 12, 2017 8:11 PM UTC

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) jumped $1.40 (33%) to $5.65 on Tuesday after reporting that ADX-102 ophthalmic solution significantly improved multiple signs and symptoms of dry eye disease in a Phase IIa trial. Next half, the company plans to start a Phase IIb trial of ADX-102. The product is a topical eye drop formulation of a small molecule that covalently binds and traps free aldehydes.

The trial enrolled 51 patients with dry eye disease to receive ADX-102 0.5% ophthalmic solution, ADX-102 0.1% ophthalmic solution or ADX-102 0.5% ophthalmic lipid solution for 28 days. On secondary endpoints, pooled data from all three arms over the 28-day treatment period showed that compared to baseline ADX-102 significantly improved Symptom Assessment in Dry Eye (SANDE) score (p=0.003), Ocular Discomfort Score (p=0.00002), Overall 4-Symptom Score (p=0.0004), tear volume as measured by Schirmer's test (p=0.008), tear osmolarity (p=0.003) and Lissamine Green ocular surface staining score (p=0.002). No serious adverse events were reported...

BCIQ Company Profiles

Aldeyra Therapeutics Inc.